A Novel Sandwich ELISA supports the Histoplasma capsulatum M antigen as a urinary biomarker for Histoplasmosis in immunocompromised patients
This study developed and validated a novel sandwich ELISA using monoclonal and polyclonal antibodies against the recombinant *Histoplasma capsulatum* M antigen, demonstrating high sensitivity, specificity, and 96% agreement with commercial tests for the non-invasive diagnosis of histoplasmosis in immunocompromised patients.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
In the world of infectious diseases, some fungi are invisible until they are too late. One such fungus is Histoplasma capsulatum, a microscopic organism found in soil that can cause a serious illness called histoplasmosis when its spores are inhaled. For most healthy people, the infection is mild or goes unnoticed, but for those with weakened immune systems—such as patients undergoing organ transplants or living with HIV—the fungus can spread through the body and become fatal. The challenge for doctors has long been how to catch this infection early. Traditional methods rely on growing the fungus in a lab, a process that can take weeks, or looking for antibodies, which are the body's immune defenses. However, in patients whose immune systems are suppressed, the body often fails to produce enough antibodies to be detected, leaving doctors without a reliable way to diagnose the disease before it becomes severe.
To solve this, researchers have turned their attention to the fungus itself rather than the body's reaction to it. Specifically, they are looking for pieces of the fungus, known as antigens, that the body releases into the urine during an active infection. One particular piece of the fungus, called the M antigen, has shown promise as a marker because it is present in the fungus regardless of its stage of growth. While commercial tests exist to detect these markers, they sometimes miss cases, particularly in patients with lower levels of infection. A team of scientists in Argentina set out to build a new, more sensitive tool to find this M antigen, hoping to create a test that works better for the most vulnerable patients.
The researchers began by creating a new type of test called a sandwich enzyme-linked immunosorbent assay, or ELISA. Imagine a sandwich where the filling is the target antigen, and the two slices of bread are specific antibodies designed to grab onto it. To build this, the team first had to manufacture the M antigen in a lab. They used bacteria to produce two versions of the protein: a full-length version and a smaller fragment. When they tried to make antibodies against the full-length protein in mice, the animals produced very few antibodies. However, when they used the smaller fragment, the mice responded strongly, creating high levels of antibodies that could specifically target the fungus. The team then fused the spleen cells from these mice with cancer cells to create hybrid cells, known as hybridomas, which could produce a steady supply of these specific antibodies. From this process, they isolated five distinct antibodies that were highly effective at recognizing the M antigen.
Next, the team tested different combinations of these antibodies to see which pair would work best as the "bread" in their sandwich test. They discovered that using one antibody to catch the antigen and a different antibody to detect it worked well, but they found an even better approach. By pairing one of their new monoclonal antibodies (a single, precise type) with a polyclonal antibody (a mixture that recognizes many different parts of the antigen), they created a system that was exceptionally good at grabbing the target. This combination allowed them to detect the M antigen at very low levels, far lower than what their previous attempts or some existing commercial tests could achieve. They also confirmed that their new antibodies did not react with other similar fungi, ensuring that the test would not give false alarms for different infections.
To see if this new test worked in real people, the researchers applied it to urine samples from 157 patients who had received kidney transplants. These patients were at high risk for fungal infections but often had low levels of the fungus in their bodies, making them difficult to diagnose. The new test identified eight patients as positive for the M antigen. When compared to a widely used commercial test, the new method agreed with the commercial results 96% of the time. However, the new test found more positive cases than the commercial kit. In several instances where the commercial test said a patient was negative, the new test said positive, and further investigation later confirmed that those patients did indeed have the infection. This suggests that the new test is more sensitive and can spot the disease earlier, even when the amount of fungus in the urine is very small.
The study concludes that this new sandwich ELISA is a robust and promising tool for diagnosing histoplasmosis in immunocompromised patients. While the researchers note that further testing with larger groups of patients is needed to fully confirm its accuracy, the results so far are encouraging. By successfully identifying the M antigen with high sensitivity and without confusing it with other fungi, the team has provided a strong proof of concept for a non-invasive diagnostic method. This advancement could mean that doctors in the future will be able to detect dangerous fungal infections sooner, allowing for earlier treatment and better outcomes for patients whose immune systems cannot fight the disease on their own.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.